Health Update


Statement of policy regarding the Festival of Biologics USA, March 2-4, Loews resort Coronado, San Diego

Dear Attendee, 
We look forward to meeting you at the Loews Resort Coronado in San Diego for our Festival of Biologics USA.  It is important to note that San Diego is a safe destination and we have no reason to believe visiting the greater San Diego area poses any unusual risk. However, we’ve had some requests about our policy regarding the potential impact of the new coronavirus (COVID-19) on the upcoming event.  Key policies and actions are outlined below together with the project team contact details.


We have regrettably felt it appropriate to confirm that no participants from the following countries and territories will be able to take part in this year’s event:
  • China
  • Thailand
  • Japan
  • Republic of Korea
  • Hong Kong
  • Taiwan
  • Singapore
  • Malaysia
  • Macau
  • Vietnam

We also regrettably going to not be allowing participants who have visited these countries or territories at any time from 31 January to attend.


We’ll be implementing the following actions onsite:
  • No handshake / hug/ kiss policy: we respectfully ask all participants to refrain from shaking hands, hugging or kissing as a greeting.
  • Increased cleaning and disinfection across all high-volume touchpoints (catering areas, washroom doors)
  • Wide availability of hand sanitizer gel at registration, washrooms, and open shared spaces.
  • We will be spacing out the seating in the conference rooms to ensure participants have maximum space
We’re comfortable that these measures mean we can stage the event safely with no risk to you however, if you’ve any concerns please don’t hesitate to drop us a line. 

Derek Cavanagh

Project Director 

+44 2070921297

Natasha Evans

Conference Producer 

+44 2070921212


Festibval of Biologics USA


There are two parts to the Festival of Biologics: three conferences covering Antibodies, Immunotherapy, Biosimilars and an exhibition featuring solutions for pharma and biotech.